A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

~14 mi. (Madison, Wisconsin, +126 more cities)

Research Site

ER Positive, +2 more biomarkers

Breast Carcinoma

datopotamab deruxtecan

targeted therapy

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

~14 mi. (Madison, Wisconsin, +133 more cities)

University of Wisconsin Carbone Cancer Center

Multiple Myeloma

bortezomib, +4 more drugs

chemotherapy, +3 more types

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

~14 mi. (Madison, Wisconsin, +523 more cities)

Dean Hematology and Oncology Clinic, +1 more facility

Clear Cell Renal Cell Carcinoma

cabozantinib, +2 more drugs

immunotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

~14 mi. (Madison, Wisconsin, +576 more cities)

University of Wisconsin Hospital and Clinics

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~14 mi. (Madison, Wisconsin, +744 more cities)

University of Wisconsin Hospital and Clinics

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~14 mi. (Madison, Wisconsin, +269 more cities)

University of Wisconsin Hospital and Clinics

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

~14 mi. (Madison, Wisconsin, +454 more cities)

University of Wisconsin Hospital and Clinics

Classical Hodgkin Lymphoma

brentuximab vedotin, +7 more drugs

chemotherapy, +3 more types

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

~14 mi. (Madison, Wisconsin, +173 more cities)

University of Wisconsin Hospital and Clinics

B-Cell Lymphoblastic Leukemia/Lymphoma

asparaginase Erwinia chrysanthemi, +12 more drugs

chemotherapy, +2 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~14 mi. (Madison, Wisconsin, +93 more cities)

University of Wisconsin Hospital and Clinics ( Site 0037)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

~14 mi. (Madison, Wisconsin, +262 more cities)

University of Wisconsin

ER Positive, +1 more biomarker

Breast Adenocarcinoma

giredestrant, +2 more drugs

hormone therapy, +1 more type

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~14 mi. (Madison, Wisconsin, +127 more cities)

University of Wisconsin Clinical Science Center

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~14 mi. (Madison, Wisconsin, +664 more cities)

University of Wisconsin Hospital and Clinics, +1 more facility

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type